Fig. 4From: EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern SwedenEuroQoL-5 dimensions utility development according to British (UK) and Swedish (SE) preference sets in established rheumatoid arthritis treated with tumour necrosis factor inhibitorsBack to article page